Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Active:	Yes
Cancer Type:	Lung Cancer Melanoma	NCT ID:	NCT03809624
Trial Phases:	Phase II	Protocol IDs:	Ph 1 INBRX-105 (primary) NCI-2019-02844
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Inhibrx, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03809624

Summary

This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety
profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)
of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation
bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the
human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through
4-1BB agonism.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.